case_images: PMC11809239_01
case_images: Trends of triglycerides (orange bars) during the course of insulin and lipid lowering therapy. (Dates in the left column are in the format month (mm)/day (dd)/year (yy); numbers are in mg/dL, conversion to SI units (mmol/L): mg/dL x 0.0113).
case_images: luaf023f1.jpg
case_images: PMC11809239_01_luaf023f1.jpg
case_images: luaf023-F1
case_images: Rosuvastatin was commenced; however, triglycerides worsened (Fig. 1) with peak triglyceride level of 1989 mg/dL (SI 22.47 mmol/L) and lowest HDL of 18 mg/dL (SI 0.466 mmol/L).
case_images: Patient prior to (A) and after (B) ipilimumab-nivolumab combination therapy, demonstrating significant generalized loss of adipose tissue, and resultant appearance of prominent veins and musculature.
case_images: luaf023f2.jpg
case_images: PMC11809239_01_luaf023f2.jpg
case_images: luaf023-F2
case_images: There, physical examination revealed significant subcutaneous fat loss of the face, buttocks, and extremities with prominent veins and musculature (Fig. 2).
case_images: A, Low-power view (4x, hematoxylin and eosin [H&E]), of patient's excisional right leg skin biopsy, demonstrating epidermis, dermis, and atrophic subcutaneous fat. Inset of A (4x, H&E): Low-power view of age-, gender-, and site-matched skin excision demonstrating epidermis, dermis, and normal subcutaneous fat (normal control). B, Medium-power view (20x, H&E) of dermal-subcutaneous junction demonstrating involuting subcutaneous fat (arrows) in a background of lymphocytes (arrowhead) and lipophages (star). C, High-power view (40x H&E) of lipophage (star) and involuting subcutaneous fat (arrows).
case_images: luaf023f3.jpg
case_images: PMC11809239_01_luaf023f3.jpg
case_images: luaf023-F3
case_images: An excisional skin biopsy of the right leg was performed which showed changes consistent with involutional lipoatrophy/lipodystrophy (Fig. 3).